Supernus reports Q3 EPS 69c, consensus 44c

Reports Q3 revenue $175.7M, consensus $157.3M. The company said, “For the third quarter and first nine months of 2024, strong performance from the Company’s key growth drivers – Qelbree and GOCOVRI – drove significant operating earnings growth. In addition to strong growth from our key drivers, we continue to advance our product pipeline, announcing positive topline data from our open-label Phase 2a study of SPN-820 in major depressive disorder.”